25 September 2025
Preventing end-stage renal disease in Thai newly-diagnosed severe lupus nephritis patients: cost-effectiveness of alternative drug regimens (research for development of the health benefit package under the Universal Coverage scheme)
View Count
35
Share this research
Project Code
11-303-2552
Country
Thailand
Project Duration
Start : 19 February 2024
End : 19 February 2028
End : 19 February 2028
Research Status
Completed 100%
Complete Research Report
Quantity 0 files
Download Count
0 times
25 September 2025
Preventing end-stage renal disease in Thai newly-diagnosed severe lupus nephritis patients: cost-effectiveness of alternative drug regimens (research for development of the health benefit package under the Universal Coverage scheme)
About Project
Content
The purpose of this study is to compare the cost-utility of each treatment option available today in order to determine the most cost-effective treatment compared with standard treatment in the social perspective. Research methodology is an economic evaluation by using the markov model to compare the cost and utility of treatment options of new patients with lupus nephritis class III and IV. The time frame of the study is from the treatment of patients until their death. The study found that the regimen of intravenous cyclophosphamide 1000 mg per month for six months followed by an oral dose of azathioprine 50 milligram per day for three consecutive years was the best option compared to other existing options. The treatment cost could be saved through the life-time treatment in one patient. The treatment was more effective in terms of the quality of life and the increase in years lived compared with the standard treatment.
Research Type
Others
Related Technologies
Health Policies
Pharmaceuticals
Others
Funding Source
National Health Security Office (NHSO)
Research Team
Principal Researcher
Co-Researcher
Related Organizations/
Supporting Organizations
National Health Security Office (NHSO)